Compare Agilent Technologies Inc (A) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Agilent Technologies Inc trades at $128.5 (market cap $37.04B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.58 (market cap $77.30B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 2.1× Agilent Technologies Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| A | MDLZ | |
|---|---|---|
Market Cap | $37.04B | $77.30B |
Sector | Health | Consumer Staples |
52-Week High | $157.20 | $70.75 |
52-Week Low | $110.24 | $51.51 |
Enterprise Value | $38.59B | $97.40B |
Dividend Yield | 0.78% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
MDLZ trades at $60.22, down 1.13% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 75.6% analyst buy rating. Revenue grew to $38.54B in 2025, though net margin compressed to 6.36%. Recent news highlights innovation in brands like Toblerone and Sour Patch Kids, alongside a new CFO appointment and a $0.50 dividend declaration.
Outlook: Wall Street consensus target of $67.86 suggests 12.7% upside, supported by resilient snacking demand and cost management. Risks include cocoa price volatility and competitive pressures, but the stock offers value with a P/E of 29.3 and stable cash flows, positioning it for recovery if technical resistance at $61 is breached.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
